Capital 2020 Virtual Investor Conference

12 June 2020

AUM Biosciences will be presenting its oncology pipeline at the Capital 2020 Virtual Investor Conference. This event brings together companies from a range of sectors including healthcare, AI and deep technologies, and many more.

For more information, visit https://www.eventbrite.com.au/e/capital-2020-virtual-investor-conference-tickets-102941693376?aff=48HRS

To stay up to date with AUM, please connect with us on LinkedIn and Twitter

About AUM Biosciences

AUM Biosciences (AUM) is an oncology-focused Asian biotechnology company committed to developing affordable cancer therapies. Dedicated to unlocking the value in innovation, AUM harnesses the power of precision medicine and digital health to support patients, physicians and partners. AUM focuses on earlystage development of innovative treatment of cancers prevalent in Asia with the potential to address global markets.

AUM develops potent and highly selective therapeutics in oncology, with an aim to change the drug development paradigm by implementing a holistic approach to developing drugs. AUM Biosciences is led by a highly-experienced management team with over 75 years of high-quality oncology drug development experience combined.

Headquartered in Singapore, AUM is strategically positioned to work, partner and collaborate with leading research institutes, clinicians and pharmaceutical companies globally. AUM is the recipient of Frost & Sullivan’s 2019 Asia-Pacific Biotech Entrepreneurial Company of the Year. For more information, please visit www.aumbiosciences.com